Kolexia
Bouattour Mohamed Gastro-entérologie
Bouattour Mohamed
Gastro-entérologie
Hôpital Beaujon
Clichy, France
207 Activités
1.2 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Carcinome hépatocellulaire Tumeurs du foie Cholangiocarcinome Tumeurs des voies biliaires Tumeurs des canaux biliaires COVID-19 Fibrose Hépatite

Collaborateurs

Voir plus
Faivre Sandrine
Faivre Sandrine
Hôpital Beaujon, Clichy, France
Raymond Eric
Raymond Eric
Gh Paris Site Saint Joseph, Paris, France
Vilgrain Valerie
Vilgrain Valerie
Hôpital Beaujon, Clichy, France
Paradis Valerie
Paradis Valerie
Hôpital Beaujon, Clichy, France

Industries

Voir plus
Bayer
15 collaboration(s)
Dernière en 2022
Roche
12 collaboration(s)
Dernière en 2022
Genactis SAS
8 collaboration(s)
Dernière en 2022
B3TSI
6 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
KEYNOTE-966: A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma
Essai Clinique (Merck & Co.)   04 mars 2024
TOPAZ-1: A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers
Essai Clinique (AstraZeneca)   23 février 2024
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
European journal of cancer (Oxford, England : 1990)   06 février 2024
Can AtezoBev be a safe and effective option for treating hepatocellular carcinoma in patients with Child-Pugh B cirrhosis? A retrospective multicenter real-world study
Abstracts of the 56th A.I.S.F. - Italian Association for theStudy of the Liver - Annual Meeting 2024Rome, March 14th -15th, 2024   01 février 2024
RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC: A Phase 2, Open-label, Multicenter Study Investigating RP3 Oncolytic Immunotherapy in Combination With First- or Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma
Essai Clinique (Replimune Inc.)   21 décembre 2023
Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.
United European gastroenterology journal   07 décembre 2023
SAFIR-ABC10: Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial
Essai Clinique (Taiho Oncology, Inc.)   15 novembre 2023
Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison.
European journal of cancer (Oxford, England : 1990)   11 novembre 2023
TERTIO: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: a Proof of Concept Randomized Phase II Study (TERTIO - Prodige 82)
Essai Clinique (CHU Besançon)   10 novembre 2023
HESTIA: A Multicentric National Phase II Trial Assessing TIslelizumab in Monotherapy for Patients With Hepatocellular Carcinoma Child-Pugh B and ALBI Grade 1 or 2 Liver Function Score
Essai Clinique (Unicancer)   06 novembre 2023